DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC
Amgen's phase 3 trial (DeLLphi-305) showed that tarlatamab (Imdelltra) plus durvalumab (Imfinzi) improved overall survival (21.1 vs 12.7 months) and progression-free survival in extensive-stage small cell lung cancer (ES-SCLC) patients. The combination also increased objective response rates. Data were presented at the 2026 ESMO Congress and published in The New England Journal of Medicine. The trial enrolled 563 patients, with median follow-up of 15.9-16.1 months.
How this was made
The 30-second read
Why it matters
Amgen's stock may rally on the unexpected survival benefit, while competitors in SCLC may face heightened scrutiny.
Market read
First‑report Phase 3 data for a new ES‑SCLC maintenance therapy, likely to move Amgen's stock and influence oncology biotech sentiment.
What to watch
Regulatory timeline and pricing strategy for tarlatamab could moderate upside.
Background
The article reports first public disclosure of DeLLphi-305 Phase 3 results presented at ESMO and published in NEJM.
Ticker impact
Amgen announced positive Phase 3 DeLLphi-305 trial results for tarlatamab plus durvalumab in ES‑SCLC, showing significant OS and PFS improvement.
likely upward pressure as market prices in the survival data
Phase 3 data with hazard ratios ~0.4 and median OS 21.1 months are material and new, prompting investors to re‑value Amgen's oncology pipeline.
Market effects
Boosts confidence in oncology biotech sector and may lift peer biotech stocks.
Positive for US biotech market; limited direct effect elsewhere.
Highlights importance of immunotherapy advances globally.
Counterpoint
Skeptics may question durability of benefit and potential safety concerns despite efficacy.
Key entities
- CompanyAmgen
Biotech firm conducting the DeLLphi-305 trial.
- DrugDurvalumab
PD‑L1 inhibitor combined with tarlatamab.
